Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Abstract: This invention provides compositions comprising at least one protein nanoparticle comprising a protein and a non-ionic surfactant. In certain embodiments, the nanoparticle further comprises a therapeutic agent, such as a siRNA. In other embodiments, the nanoparticle further comprises a cell surface receptor ligand. Also included in the invention are methods of preparing the compositions of the present invention, and methods of treating, ameliorating or preventing a disease or disorder in a subject in need thereof using the compositions of the present invention.

Abstract: The present invention relates to a composition which includes antibodies against one or more specified virus, bacteria and/or pathogen for use to improve dog health, wherein the composition is administered before 24 hours of age of the dog or between 24 hours and up to 90 days of age of the dog.

Abstract: This invention relates to antibody therapies for human immunodeficiency virus (HIV). In particular, the invention provides methods of curing subjects infected with HIV and blocking HIV infections in subjects at risk of HIV transmission using a N332 glycan-dependent antibody (e.g., PGT121).

Abstract: A method for treating a microbial infection involves administering an effective amount of a compound of the formula: wherein R1 is H, alkyl, aryl, heteroaryl, R2 is H, halogen, alkyl, aryl, heteroaryl, R3 is H, hydroxyl, alkoxy, alkyl, aryl, heteroaryl, amino, amino sulfonyl, acetamide, R4 is H, hydroxyl, alkoxy, alkyl, aryl, heteroaryl, amino, amino sulfonyl, acetamide, R5 is H, hydroxyl, alkoxy, alkyl, aryl, heteroaryl, amino, amino sulfonyl, acetamide, R6 is H, hydroxyl, alkoxy, alkyl, aryl, heteroaryl, amino, amino sulfonyl, acetamide, R7 is H, hydroxyl, alkoxy, alkyl, aryl, heteroaryl, amino, amino sulfonyl, acetamide, R8 is —CR3, O, S, wherein R5 and R6, R7 and R6, R5 and R4, R4 and R3 can cyclize forming a 3-10 member ring comprising C, O, S, and/or N optionally substituted with one or more R3; and administering light therapy, such as a photodynamic therapy (PDT) light source.

Abstract: The present invention relates to a liposome composition comprising 0.001 to 5% by weight of conjugate of lysophophatidylcholine and chlorin e6, 1 to 10% by weight of sucrose laurate, 0.1 to 5% by weight of sodium stearoyl glutamate, 1 to 10% by weight of PEG-5 rapeseed sterol, 1 to 20% by weight of medium-chain triglyceride, 1 to 10% by weight of vegetable oil, 0.1 to 5% by weight of sodium deoxycholate, 3 to 10% by weight of glycerin and the balance of water, and a skin care composition comprising the same. The liposome composition of the present invention is very effective in the treatment of acne.

Abstract: A pharmaceutical composition for oral use including a release formulation formed by extrusion, said formulation in particular including a polyurethane polymer and an active agent. A process of manufacturing the formulation, uses and methods of treatment.

Abstract: The present invention proposes a formulation and the process to prepare thick water to be administered to patients afflicted by dysphagia. It particularly comprises of a polymer that helps the formulation to stay thick when administered and thins out as it passes to the stomach. The formulation does not regain viscosity when it enters duodenum and small intestine regions. This formulation for the management of dysphagia can be prepared at any consistency/viscosity required. Some of the advantages proposed are a decrease in feeling of satiety, ease of administration and no effect on the bioavailability of co-administered medications.

Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.

Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.

Abstract: The invention provides methods for preparing an antibody-active agent conjugate. The conjugate comprises an antibody, a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody, an isoprenoid unit operably linked to the cysteine residue, and an active agen. The invention also provides a composition comprising the antibody-active agent conjugate prepared by the methods.

Abstract: There is provided polymer-flavonoid conjugates. Flavonoid-grafted and flavonoid-terminated polymer conjugates are disclosed according to the invention. The linkage of flavonoids to the polymers has been achieved via thiol linkages. The inventive processes allow for making of the conjugates in high yield avoiding complex purification steps. The conjugates can be easily autoxidized to hydrogels with uses in many biomedical applications where a higher stability of the flavonoid is necessary. The hydrogels can be potentially used as viscosupplement, anti-adhesion film or dermal filler.

Abstract: Disclosed is a composite. The composite comprises a nanocarrier and targeting molecules coupled to a surface of the nanocarrier. The particle size of the nanocarrier is smaller than 200 mn, and the polydispersity index (PDI) is smaller than 0.5. Also disclosed are an antitumor medicament comprising the composite and antitumor drug carried in the nanocarrier of composite, a preparation method therefor, and uses thereof. The composite can convey the antitumor drug into a tumor cell, and has a strong killing effect to the tumor cell.

Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.

Abstract: A new nanoscale carrier made by one or more pH-sensitive peptides is provided for delivery of a biologically active substance. The peptides are composed of pH-sensitive hydrophilic and hydrophobic amino acids in the backbone. As the pH environment changes from physiological pH level to a weakly acidic environment such as near a tumor site (pH˜6.5-6.9), the peptides may dissolve, releasing the biological substance. Also provided are the delivery methods and related kits.

Abstract: The present disclosure relates to methods for detecting a biological parameter and to sensors for detecting a biological parameter. Certain embodiments of the present disclosure provide a method of detecting a biological parameter in a subject, the method comprising: implanting a sensor into the subject, wherein the sensor comprises an optical reflectance property between 400 and 1200 nm which is responsive to the biological parameter; detecting an optical reflectance property between 400 and 1200 nm through the skin of the subject from the implanted sensor, and using the optical reflectance property to detect the biological parameter.

Abstract: Probes which target diffuse and fibrillar forms of amyloid beta (A?) are described. These probes demonstrate high initial brain penetration and facile clearance from non-targeted regions. The agents can be used to image amyloid quantitatively for monitoring efficacy of A?-modifying therapeutics and assist in premortem diagnosis of Alzheimer's disease (AD). Disclosed probes can bind A? aggregates of preformed A?1-42 fibrils in vitro and can be used to image fibrillar and diffuse plaques ex vivo in brain sections. Disclosed probes can be used to determine A? burden in early stages of AD. These probes can be used for multimodality imaging of A?. F-AI-187(1 ?M) can detect A? plaques in brain sections of APP/PS1 mice. F-AI-187(10 ?M) can detect A? plaques in the frontal lobe in a brain section of a patient with confirmed AD. Some probes can be used for fluorescence imaging of plaque.

Abstract: Provided are therapeutic and diagnostic somatostatin analogs including radiotherapeutic and radiodiagnostic reagents, and methods of making and use thereof.

Abstract: The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from epigallocatechin Gallate (EGCg), which is a polyphenols- or flavanoids-rich plant material that can be obtained from green tea. The EGCg is an antioxidant reducing agent derived from green tea. The gold nanoparticles of the invention can be radioactive or non radioactive and are formed via a simple room temperature fabrication method. Therapy and sensing methods are conducted with nanoparticles of the invention.

Abstract: A method is disclosed for producing a sterilized medical formed article that includes applying high-energy rays to a medical formed article at an exposure E. The medical formed article is formed of a resin composition that includes a hydrogenated block copolymer and a phenol-based antioxidant. The hydrogenated block copolymer is obtained by hydrogenating 99% or more of unsaturated bonds of a block copolymer that includes at least two polymer blocks [A] and at least one polymer block [B], the polymer block [A] including a repeating unit derived from an aromatic vinyl compound as a main component, the polymer block [B] including a repeating unit derived from a linear conjugated diene compound as a main component, and a ratio (wA:wB) of a weight fraction wA of the polymer block [A] to a weight fraction wB of the polymer block [B] being 30:70 to 70:30.

Abstract: Low energy electron sterilizers and method of sterilization using low energy electrons are disclosed herein. An example method of sterilizing an instrument using low energy electrons can include generating one or more low energy electrons, maintaining the instrument in a vacuum and irradiating the instrument with the low energy electrons. The low energy electrons can have an energy less than or equal to 25 ke V, and the vacuum can be sufficiently low to prevent the one or more electrons from producing a plasma.

Abstract: A disinfecting unit and method of operating the same includes a cabinet and a support arm having a first position within the cabinet and a second position at least partially outside the cabinet. A lamp arm is rotatably coupled to the support arm. The support arm comprises a folded position in the first position and an unfolded position in the second position. A lamp is coupled to the lamp arm. A nebulizer is coupled to the cabinet that dispenses disinfecting fluid therethrough.

Abstract: Introducing ultraviolet (UV) light to interior portions of footwear alters the environment inside a shoe or other footwear to destroy microorganisms or inhibit their growth. Visible light can also be used to prevent further microorganism growth. Introducing forced air flow through the footwear removes dampness in and thereby deodorizes the footwear. A preferred embodiment comprises an adjustable shoe tree equipped with a UV germicidal light source and electronic safeguards that prevent appreciable leakage of UV radiation outside the shoe.

Abstract: A scent preventer comprising sodium bicarbonate and methods of its use are disclosed comprising an odorless plastic bag into which, prior to going into the field, the clothes of a hunter are inserted together with the scent preventer of a measured amount of sodium bicarbonate (Na HCO3). Then the bag is closed, shaked, and stored for up to two days prior to removal of the clothes of the hunter which are thereby rendered odor and scent free.

Abstract: An electrical plug in fragrance dispenser can include a removable decorative sheath. The dispenser can be configured so that, when the sheath is attached, an electrical outlet is completely covered. In this way, the dispenser will have the appearance of a more permanent decorative light fixture. The dispenser can also be configured to plug into two outlets of an electrical receptacle thereby increasing the stability of the dispenser when attached to the wall or other surface. The dispenser may also include an outlet so that the receptacle can still be used when the dispenser is secured overtop the receptacle.

Abstract: A vehicle system includes a container adapted to hold a fluid fragrance substance, a pump connected to the container, a capillary pipe connected to the pump and sized to retain the fluid fragrance substance within the capillary pipe when the pump is off, and an evaporation grid connected to the capillary pipe. The evaporation grid may have open porosity and be at least partially positioned within a vehicle ventilation channel to selectively provide fragrance to the vehicle.

Abstract: In some embodiments, a scalable airborne pathogen removal system may comprise a housing having an airspace inlet which may be configured to receive air; a supplemental inlet located proximate to the airspace inlet configured to receive supplemental air; and an airspace outlet configured to communicate air from the housing into the airspace. The housing may include a treatment chamber in fluid communication with the airspace inlet, supplemental inlet, and airspace outlet. A first baffle may be positioned within the housing between the airspace inlet and the treatment chamber. Supplemental air from the supplemental inlet may be communicated into the treatment chamber through the first baffle. An ultraviolet light may be disposed within the treatment chamber. An air motivator may be positioned between the treatment chamber and the airspace outlet which may be configured to pull air from the airspace inlet and supplemental inlet through the treatment chamber.

Abstract: The invention relates to novel absorbent fibres/filaments from low-substituted carboxymethyl cellulose and the method of producing same. The filaments are produced by wet spinning, wherein the spinning dope is entirely comprised of low-substituted carboxymethyl cellulose dissolved in sodium hydroxide. The resulting CMC filaments have degree of substitution ranging from 0.10-0.35 and degree of polymerization ranging from 250-650 with the CMC uniformly distributed throughout the filament. The absorbency in deionized water and saline (0.9% NaCl) solution is 120 g/g and 30 g/g, respectively. The retention of deionized water and saline (0.9% NaCl) solution within the fibres is 48 g/g and 25 g/g, respectively.

Abstract: A package of diapers is provided for treating diaper rash, where the package of diapers includes a first diaper and a second diaper. The first diaper includes an absorbent layer configured to absorb moisture away from a wearer of the first diaper and a topical layer applied on the absorbent layer of the first diaper in a first pattern. The second diaper includes an absorbent layer configured to absorb moisture away from a wearer of the second diaper and a topical layer applied of the absorbent layer of the second diaper in a second pattern, where the first pattern is different than the second pattern.

Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Abstract: Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

Abstract: A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Abstract: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug.

Abstract: A biodegradable bioprosthesis can include a biodegradable tissue and a biodegradable polymer combined with the biodegradable tissue. The biodegradable tissue can be non-crosslinked tissue, EDC crosslinked tissue or tissue crosslinked using biodegradable crosslinker. The biodegradable polymer can be a crosslinked polymer and/or synthetic polymer. The bioprosthesis can include a bioactive agent (rifampin). The biodegradable tissue and biodegradable polymer can form a drug delivery patch having the bioactive agent. The bioactive agent can be an antimicrobial. The biodegradable tissue can be decellularized. A method of making the biodegradable bioprosthesis can include treating the biodegradable tissue with a fluid having the biodegradable polymer. A method of implanting a biodegradable bioprosthesis can include implanting the bioprosthesis in a subject, where the bioprosthesis is implanted for repairing a hernia and/or the bioprosthesis inhibits post-operative adhesions.

Abstract: This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.

Abstract: Certain embodiments described herein are directed to cohesive materials comprising treated, derivatized collagen molecules. In some embodiments, the cohesive material can function as a putty or defect filler that can be used in a tissue repair. Methods of using the cohesive materials are also described.

Abstract: Biodegradable implants including an ECM material and methods for treating a pelvic floor condition are described. ECM particles can be present within or on the surface of a pelvic implant, such as a biodegradable mesh, a pouch, or a urethral stent. After implantation the implant can provide tissue support, degrade over a period of time, and deposit the ECM material in the implantation area for regeneration of tissue and long term benefit.

Abstract: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. This invention also relates to a medical device including said biomaterial and to a method of repair or treatment including the filling of cavities in the human face or body.

Abstract: Disclosed herein are dry blends of polyanionic and polycationic macromolecules, solvating fluids serving as cell suspension fluids, hybrid gel compositions, and methods for treatment of patients with endocrine disorders by transplantation with such compositions. Hybrid gel compositions that promote a microenvironment suitable for cell viability and growth while maintaining a sufficient structural integrity for three-dimensional cell culture are also disclosed.

Abstract: Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided.

Abstract: An acicular body includes a support plate having a brightness of 5.0 or less, and a needle disposed on the support plate. The needle includes a tip formed to pierce a skin and a light transmission area which is located in an area including the tip and has a total light transmittance of 20% or more.

Abstract: Provided are a metal medical device such as a guide wire or stent in which a lubricant layer is firmly bonded to the surface of the metal medical device to impart lubricity and low protein adsorption properties and/or low cell adsorption properties to the surface and, further, improve the durability of the lubricant layer on the surface of the metal medical device, thereby suppressing deterioration of sliding properties and deterioration of low protein adsorption properties and/or low cell adsorption properties, and a method for preparing such a metal medical device. The present invention relates to a metal medical device having lubricity and low protein adsorption properties and/or low cell adsorption properties, the device having a surface at least partially treated with a silane compound containing a functional group, the functional group being a polyoxyalkylene group, a metal salt-containing hydrophilic group, a halogen salt-containing hydrophilic group, or a fluorine-containing hydrophobic group.

Abstract: Implantable medical devices are provided. In one embodiment, a device includes a body having an external surface defining an outer profile of the device. The body includes a porous matrix including a series of interconnected macropores defined by a plurality of interconnected struts each including a hollow interior. A filler material substantially fills at least a portion of the series of interconnected macropores. The external surface of the body includes a plurality of openings communicating with the hollow interior of at least a portion of the plurality of interconnected struts. In a further aspect of this embodiment, the external surface includes exposed areas of the filler material and porous matrix in addition to the exposed openings. In another aspect, the porous matrix is formed from a bioresorbable ceramic and the filler material is a biologically stable polymeric material. Still, other aspects related to this and other embodiments are also disclosed.

Abstract: A reduced-pressure canister includes a canister body having a fluid reservoir, an inlet for receiving fluids from a patient, and an integral hydrophobic filter formed within a side or top portion of the canister body. The integral hydrophobic filter has a plurality of pores in the canister body that are covered by a hydrophobic coating. Other canisters, methods, and systems are also presented.

Abstract: A negative pressure wound therapy (NPWT) orthopedic device includes a base shell and a dorsal shell contoured to generally correspond to an opening of the base shell. The dorsal shell includes a proximal section and a distal section. The proximal section at least in part defines a receiving space. A NPWT system includes a pump mechanism secured in the receiving space and a wound covering situated inside of the base shell and arranged to form a sealed volume over a wound area of a user. At least one conduit forms a fluid connection between the wound covering and the pump mechanism. The pump mechanism is arranged to apply a negative pressure to the wound area through the at least one conduit.

Abstract: A receptacle for breast milk extraction using an external vacuum source and method of extraction are disclosed. The receptacle may include an open end for receiving a breast and a vacuum transfer zone on an outer surface thereof. The vacuum transfer zone may have a surface area of at least 1 cm2 and the vacuum transfer area may be in pressure communication with an interior of the receptacle and the external vacuum source. A deformable diaphragm may block fluid communication between said interior of the receptacle and said external vacuum source. The diaphragm may limit a volume change associated pressure fluctuations. The receptacle and/or the diaphragm may be single use. Milk may optionally be collected into a flexible single use collection and/or storage vessel.

Abstract: A catheter pump includes an impeller and a drive shaft coupled with the impeller. The catheter pump includes a motor assembly coupled with the drive shaft. The motor assembly includes a motor housing having an opening through a wall of the motor housing and a flexible member disposed about the opening, the flexible member configured to engage a connection portion of a platform.